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We investigated whether progranulin plasma levels are predictors of the presence of progranulin gene
(GRN) null mutations or of the development of symptoms in asymptomatic at risk members participating
in the Genetic Frontotemporal Dementia Initiative, including 19 patients, 64 asymptomatic carriers, and
77 noncarriers. In addition, we evaluated a possible role of TMEM106B rs1990622 as a genetic modifier
and correlated progranulin plasma levels and gray-matter atrophy. Plasma progranulin mean  SD
plasma levels in patients and asymptomatic carriers were significantly decreased compared with non-
carriers (30.5  13.0 and 27.7  7.5 versus 99.6  24.8 ng/mL, p < 0.00001). Considering the threshold of
>61.55 ng/mL, the test had a sensitivity of 98.8% and a specificity of 97.5% in predicting the presence of a
mutation, independent of symptoms. No correlations were found between progranulin plasma levels and
age, years from average age at onset in each family, or TMEM106B rs1990622 genotype (p > 0.05). Plasma
progranulin levels did not correlate with brain atrophy. Plasma progranulin levels predict the presence of
GRN null mutations independent of proximity to symptoms and brain atrophy.
 2017 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Mutations in progranulin gene (GRN) are associated with
familial forms of frontotemporal dementia (FTD). The majority of
mutations cause haploinsufficiency and are associated with anondazione Cà Granda, IRCCS
athophysiology and Trans-
Tel.: þ390255033847; fax:
limberti).
er Inc. This is an open access articextremely heterogeneous clinical presentation (Woollacott and
Rohrer, 2016) and TAR DNAebinding protein-43 pathology
(Neumann et al., 2006). Progranulin displays anti-inflammatory
properties but can also undergo cleavage to produce granulins,
which, conversely, have proinflammatory properties (Tang et al.,
2011). Abnormalities of several cytokines and chemokines has
been observed in cerebrospinal fluid (CSF) of GRN carriers
compared with controls (Galimberti et al., 2015), suggesting an
imbalance of specific inflammatory factors possibly related to GRN
haploinsufficiency.le under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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mutations in GRN display very low plasma progranulin levels
compared with sporadic FTD (Finch et al., 2009; Ghidoni et al.,
2008; Sleegers et al., 2009), and that this analysis is useful to
identify carriers of mutation causing haploinsufficiency, indepen-
dent of the clinical presentation (Carecchio et al., 2009). A multi-
center Italian study, carried out among subjects attending to a
memory clinic, suggested a cutoff level of 61.55 ng/mL, which was
able to identify null mutation carriers with a sensitivity of 95.8%
and a specificity of 99.6% (Ghidoni et al., 2012). Despite its prom-
ising role as a biomarker for predicting the presence of a mutation
and thus avoiding sequencing, which is expensive and time
consuming, caution should be taken in using plasma progranulin
levels to predict changes in the brain. In fact, progranulin levels are
differently regulated in plasma and CSF, therefore peripheral levels
may not adequately represent progranulin levels in the central
nervous system (Nicholson et al., 2014; Wilke et al., 2016).
Recently, it has been demonstrated in the Genetic Fronto-
temporal Dementia Initiative (GENFI) study that gray matter and
cognitive changes can be identified 5e10 years before the expected
onset of symptoms in adults at risk of genetic FTD, including a
cohort carrying GRN mutations (Rohrer et al., 2015). Brain atrophy
in presymptomatic carriers of common FTD mutations, including
GRN, is affected by both genetic and environmental factors such as
TMEM106B rs1990622 polymorphism (Finch et al., 2011). This gene
has been actually demonstrated to act as a genetic modifier of GRN
mutations, influencing the age at disease onset and progranulin
levels in mutation carriers (Cruchaga et al., 2011; Finch et al., 2011).
Carriers of 2 copies of the minor allele of rs1990622 have a signif-
icantly reduced penetrance or the onset significantly delayed (Finch
et al., 2011).
Given these premises, the main aim of this study was to test the
sensitivity and specificity of progranulin plasma levels as predictors
of the presence of GRN null mutations in asymptomatic at risk
members of families with known mutations enrolled in GENFI.
Additional objectives include the analysis of (1) the TMEM106B
rs1990622 genotype as a genetic modifier, and (2) the correlation
between progranulin plasma levels and cortical gray-matter atro-
phy in both symptomatic and asymptomatic subjects.1. Methods
1.1. Study participants
Data for this study were drawn from the GENFI multicentre
cohort study (Rohrer et al., 2015). Eight centers participated in this
study from the UK, Italy, the Netherlands, Sweden, Portugal, and
Canada. Inclusion and exclusion criteria have been previously
described (Rohrer et al., 2015). Local ethics committees approved
the study at each site and all participants provided written
informed consent. For the aim of the present work, we considered
participants from GRN families including those who had already
developed symptoms as well as their at-risk relatives (which
includes bothmutation carriers and noncarriers). Samples from 160
Caucasian subjects belonging to 42 families were available,Table 1
Characteristics of the GENFI cohort of families with GRN mutations
Population Symptomatics
N 19
Age  SD (range) 64.3  5.71 (55e77)
Sex (M:F) 8:11
Mean progranulin plasma levels  SD (ng/mL) 30.5  13.0
Key: GENFI, Genetic Frontotemporal Dementia Initiative; SD, standard deviation.including 19 patients [11 females and 8 males, mean age (years) at
time of inclusion  standard deviation (SD) 64.3  5.71, range
(years): 55e77]; 64 asymptomatic carriers (43 females and 21
males, mean age SD 49.1 11.1, range 26e70), and 77 noncarriers
(49 females and 28 males, mean age  SD 49.6  15.3, range
19e86). In accordance with the Genfi protocol, samples were
collected in the morning after an overnight fasting and processed
without delay locally, likely avoiding stability issues and intra-
individual variations. All subjects underwent a careful recording
of demographic data, including years of formal schooling, past
medical history, a standardized clinical and neuropsychological
assessment, as previously published, and T1-weighted MRI scan for
volumetric analysis (Rohrer et al., 2015). Characteristics of the
cohort studied are summarized in Table 1.
1.2. DNA isolation
Total genomic DNA was isolated from whole blood using a
Flexigene Kit (Qiagen, Hildren, Germany), according to the manu-
facturer instructions. The amount of DNA for each sample was
determined by measuring the optical density at 260-nm wave-
length using a spectrophotometer (Eppendorf AG, Wesseling-
Berzdorf, Germany). DNA samples were aliquoted and stored
at 20 C until use.
1.3. Genotyping
The entire open reading frame including the noncoding exon
0 and exon-intron boundaries of exons 1e12 of the GRN gene was
sequenced using specific primers (available upon request) on an
AB3130 automated sequencer (Applied Biosystems). Chromato-
gram analysis was carried out using SeqScape software version 2.5
(Applied Biosystem, Foster City, CA, USA). TMEM106B rs1990622
(C/T) single nucleotide polymorphism genotyping was performed
according to standard procedures (Premi et al., 2014).
1.4. Plasma sample collection and progranulin level evaluation
EDTA blood samples were allowed to sit at room temperature for
a minimum of 30 minutes and a maximum of 2 hours, after
collection. Separation of the clot was done by centrifugation at
1000e1300  g at room temperature for 15e20 minutes. Plasma
was removed and dispensed in aliquots of 400 mL into cryo-tubes.
Specimens were stored at 80 C until use.
Progranulin levels were tested with a specific ELISA kit (Adipo-
gene, Korea), using polyclonal specific antibodies. According to the
manufacturer’s protocol, the test has a 5.1% CV within an assay
(intra-assay precision) and 6.4% CV precision between assays
(interassay precision). The limit of detection is 32 pg/mL, with an
assay rangeof0.063e4ng/mL. The linearity ranges from93% to102%.
1.5. Statistical analysis
Descriptive statistics, including means and standard deviations,
or counts and percentages were calculated. For plasma progranulinAsymptomatics at risk Noncarriers
64 77
49.1  11.1 (26e70) 49.6  15.3 (19e86)
21:43 28:49
27.7  7.5 99.6  24.8
D. Galimberti et al. / Neurobiology of Aging 62 (2018) 245.e9e245.e12 245.e11levels, 1-way ANOVA with post hoc Dunn’s test for multiple
comparisons was used. The level of statistical significancewas set at
p < 0.05.
TMEM106B rs1990622 allelic and genotypic frequencies were
compared with the Fisher test. The odds ratio was calculated along
with its 95% confidence interval.
1.6. Imaging analysis
Participants underwent volumetric T1-weightedMR imaging on
a 3T or 1.5T scanner at sites where 3T was not available, performed
usually on the same day as serum sampling but at a maximum of
12 weeks from the time of sample collection (Rohrer et al., 2015).
Only mutation carriers (presymptomatic and symptomatic
subjects) were included in the analysis.
Two separate analyses were performed. First, progranulin levels
were correlatedwith defined regions of interest, specifically cortical
gray-matter volumes (corrected for total intracranial volume) of the
insula, cingulate, frontal, temporal, parietal, and occipital lobes that
were generated using a previously described methodology (Rohrer
et al., 2015). Second, a voxel-wise analysis was performed to assess
the correlation of progranulin levels with gray-matter intensity:
this voxel-based morphometric analysis was implemented using
SPM12 (http://www.fil.ion.ucl.ac.uk/spm) adjusting for age, gender,
total intracranial volume, and MR scanner.
2. Results
Subjects included were members of families with the following
GRN mutations: D22fs (n ¼ 2), C31fs (n ¼ 3), G35fs (n ¼ 9), S82fs
(n ¼ 37), Q125X (n ¼ 16), Q130fs (n ¼ 7), C149fs (n ¼ 5), C157fs
(n ¼ 1), Q249X (n ¼ 12), Q257fs (n ¼ 2), T272fs (n ¼ 44), W386X
(n ¼ 3), V411fs (n ¼ 3), C416fs (n ¼ 5), C474fs (n ¼ 1), R493X
(n ¼ 10).
Mean  SD levels in patients and asymptomatic carriers were
significantly decreased compared with noncarriers (30.513.0 and
27.7  7.5 versus 99.6  24.8 ng/mL, respectively, p < 0.00001,
Fig. 1). Considering the threshold of 61.55 ng/mL, the test had a
sensitivity (positive test/number of subjects carrying mutations at
sequencing) of 98.8% and a specificity (negative test/total subjectsAs
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Fig. 1. Box and whiskers plot of progranulin plasma levels. The dotted line indicates
the proposed threshold (61.55 ng/mL). *p < 0.001.without mutations at sequencing) of 97.4% in predicting the pres-
ence of a mutation, independent of symptoms.
No correlations were found between progranulin plasma levels
and age or years from expected average age at onset in each family
(p > 0.05, data not shown).
The TMEM106B rs1990622 status was available in 141 subjects.
None of the symptomatic subjects (n¼ 12) carried the protective CC
genotype. The mean age at onset was similar in patients carrying
the TT (n ¼ 6) compared with TC (n ¼ 6) carriers (p > 0.05).
No significant differences in plasma progranulin levels were
observed after stratifying for the rs1990622 genotype (p > 0.05).
Neither of the imaging analyses showed significant correlations
of gray matter with progranulin levels (data not shown).
3. Discussion
These data demonstrate that progranulin plasma levels repre-
sent an excellent predictor of the presence of a null GRN mutation
independent of symptom proximity and brain atrophy. Therefore,
besides its suggested use in clinical settings to identify people to be
further screened by sequencing, it could be extremely useful in the
future to identify potential subjects to be included in preclinical
preventive trials to replace progranulin expression. Results shown
here confirm those previously obtained in an Italian population
(Ghidoni et al., 2012), suggesting that the cutoff of 61.55 ng/mL
would be the best threshold to have an optimal sensitivity and
specificity for identifying people carrying a GRN null mutation.
Considering the low cost of the test and the heterogeneity of clinical
presentation and age at onset of the disease in GRN carriers, this test
could be proposed as routine screening among subjects attending
memory clinics.
We acknowledge however that progranulin levels are differently
regulated in CSF and plasma, and thus it is likely that peripheral
levels do not fully reflect the pathogenic cascade ongoing in the
central nervous system (Nicholson et al., 2014; Wilke et al., 2016). It
is worth noting that progranulin dysregulation is more than
expected based on the haploinsufficiency disease mechanism,
according to which the wild-type allele would be expressed, thus
leading to 50% protein production. Although the mechanisms
linking progranulin haploinsufficiency with neurodegeneration are
not yet understood, our results show that the deregulation of
progranulin expression is a very early event during the lifespan of
carriers, as very low levels were observed, in presymptomatic
individuals, even in the second or third decade of life, that is, long
before themean age at which symptoms appeared in the family and
far from the time at which brain atrophy is observed. This result has
profound implications regarding the development of tailored
treatments for GRN mutation carriers, which should prevent the
de-regulation of this gene rather than cure the disease once there is
evidence of gray matter atrophy and cognitive changes, previously
shown to occur 5e10 years before the appearance of symptoms
(Rohrer et al., 2015). So far, in linewith the hypothesis that restoring
progranulin levels may be an effective therapy, a few clinical trials
with compounds able to do this have been carried out in patients
but have failed (see Tsai and Boxer, 2016, for review).
The penetrance of GRN mutations is likely influenced by many
other genetic factors, primarily the TMEM106B genotype. In this
regard, although we analyzed a quite small cohort of symptomatic
subjects, it is worth underlining that none of the patients were a
carrier of the protective rs1990622 CC genotype, thus supporting
the evidence that this polymorphism acts as a genetic modifier in
GRN carriers (Cruchaga et al., 2011; Finch et al., 2011; Lattante et al.,
2014).
In conclusion, the evaluation of progranulin plasma levels is an
excellent predictor of the presence of a null mutation in GRN but is
D. Galimberti et al. / Neurobiology of Aging 62 (2018) 245.e9e245.e12245.e12instead of poor utility as proximity marker, that is, predicting the
development of symptoms and the prognosis. Considering the
heterogeneity of clinical phenotypes and age at onset associated
with such mutations and that the analysis is not invasive and low
cost, it could be introduced as a routine analysis to be carried out in
people attending memory clinics to identify subjects to be further
studied by sequencing and in the future extended to at-risk
individuals for preventive therapies.
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